138 related articles for article (PubMed ID: 17446118)
21. [Experimental study of adoptive immunotherapy using CD3AK cells].
Sun YX; Cheng SH; Yu M; He YH; Lai CN; Li Y; Shen BF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):218-21. PubMed ID: 15766410
[TBL] [Abstract][Full Text] [Related]
22. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
Parlevliet KJ; ten Berge IJ; Yong SL; Surachno J; Wilmink JM; Schellekens PT
J Clin Invest; 1994 Jun; 93(6):2519-25. PubMed ID: 8200988
[TBL] [Abstract][Full Text] [Related]
23. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
24. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
25. Generation and characterization of a high-affinity chimaeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
Biotechnol Appl Biochem; 2006 Feb; 43(Pt 2):93-101. PubMed ID: 16253117
[TBL] [Abstract][Full Text] [Related]
26. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
27. In vivo T cell activation properties of anti-T cell monoclonal antibodies.
Ferran C; Bach JF; Chatenoud L
Exp Nephrol; 1993; 1(2):83-9. PubMed ID: 8081961
[TBL] [Abstract][Full Text] [Related]
28. The design, construction and function of a new chimeric anti-CD20 antibody.
Wang Y; Feng J; Huang Y; Gu X; Sun Y; Li Y; Shen B
J Biotechnol; 2007 May; 129(4):726-31. PubMed ID: 17433484
[TBL] [Abstract][Full Text] [Related]
29. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
[TBL] [Abstract][Full Text] [Related]
30. Differential antibody binding to the surface alphabetaTCR.CD3 complex of CD4+ and CD8+ T lymphocytes is conserved in mammals and associated with differential glycosylation.
Rossi NE; Reiné J; Pineda-Lezamit M; Pulgar M; Meza NW; Swamy M; Risueno R; Schamel WW; Bonay P; Fernández-Malavé E; Regueiro JR
Int Immunol; 2008 Oct; 20(10):1247-58. PubMed ID: 18653700
[TBL] [Abstract][Full Text] [Related]
31. Selective immunosuppression with anti-T cell monoclonal antibodies.
Chatenoud L; Bach JF
Clin Nephrol; 1992; 38 Suppl 1():S53-60. PubMed ID: 1295709
[TBL] [Abstract][Full Text] [Related]
32. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.
Sasaki N; Yamashita T; Takeda M; Shinohara M; Nakajima K; Tawa H; Usui T; Hirata K
Circulation; 2009 Nov; 120(20):1996-2005. PubMed ID: 19884470
[TBL] [Abstract][Full Text] [Related]
33. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
[TBL] [Abstract][Full Text] [Related]
36. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange.
Geng SS; Feng J; Li Y; Sun Y; Gu X; Huang Y; Wang Y; Kang X; Chang H; Shen B
Cell Mol Immunol; 2006 Dec; 3(6):439-43. PubMed ID: 17257497
[TBL] [Abstract][Full Text] [Related]
37. Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity.
Qian W; Wang L; Li B; Wang H; Hou S; Hong X; Zhang D; Guo Y
Biochem Biophys Res Commun; 2008 Mar; 367(2):497-502. PubMed ID: 18190781
[TBL] [Abstract][Full Text] [Related]
38. Construction of a recombinant non-mitogenic anti-human CD3 antibody.
Hinojosa LE; Hernández T; de Acosta CM; Montero E; Pérez R; López-Requena A
Hybridoma (Larchmt); 2010 Apr; 29(2):115-24. PubMed ID: 20443703
[TBL] [Abstract][Full Text] [Related]
39. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
40. Anti-inflammatory effects of Artemisia princeps in antigen-stimulated T cells and regulatory T cells.
Chang SH; Jung EJ; Park YH; Lim DG; Ko NY; Choi WS; Her E; Kim SH; Choi KD; Bae JH; Kim SH; Kang CD; Han DJ; Kim SC
J Pharm Pharmacol; 2009 Aug; 61(8):1043-50. PubMed ID: 19703348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
